Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „axitinib“
Suchtreffer
Begriffe & Kennungen
Artesunate Amivas · 4.5 · Co-administration of intravenous artesunate with strong inhibitors of UGT enzymes (e.g. axitinib, vandetanib,
Eintrag öffnenAxitinib
Eintrag öffnenBavencio · 4.8 · 14 In patients treated with avelumab in combination with axitinib, 0.6% (3/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · 16 In patients treated with avelumab in combination with axitinib, 1.8% (9/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · Among the 73 patients who were rechallenged with either avelumab (59%) or axitinib (85%) monotherapy or with b
Eintrag öffnenBavencio · 4.8 · Hepatotoxicity (in combination with axitinib) In patients treated with avelumab in combination with axitinib,
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 2.7% (13/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 24.7% (121/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 6.3% (31/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, Type 1 diabetes mellitus without an alternativ
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, immune-mediated nephritis occurred in 0.4% (2/
Eintrag öffnenBavencio · 4.8 · Table 3: Adverse reactions in patients treated with avelumab in combination with axitinib
Eintrag öffnenBavencio · 4.8 · The safety of avelumab in combination with axitinib has been evaluated in 489 patients with advanced RCC recei
Eintrag öffnenInlyta · 4.3 · Hypersensitivity to axitinib or to any of the excipients listed in section 6.1.
Eintrag öffnenInlyta · 4.5 · CYP1A2 and CYP2C19 inhibitors CYP1A2 and CYP2C19 constitute minor (< 10%) pathways in axitinib metabolism. The
Eintrag öffnenInlyta · 4.5 · Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbam
Eintrag öffnenInlyta · 4.5 · In vitro data indicate that axitinib is metabolised primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP
Eintrag öffnenInlyta · 4.5 · In vitro studies also indicated that axitinib has the potential to inhibit CYP2C8. However, co-administration
Eintrag öffnenInlyta · 4.5 · In vitro studies in human hepatocytes also indicated that axitinib does not induce CYP1A1, CYP1A2, or CYP3A4/5
Eintrag öffnenInlyta · 4.5 · In vitro studies indicated that axitinib has a potential to inhibit CYP1A2. Therefore, co-administration of ax
Eintrag öffnen